Biomarker ID | 460 |
PMID | 19491931 |
Year | 2009 |
Biomarker | IGF1 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | NA |
Subjects | Humans |
Regulation | Higher concentrations in patients with decreased risk of advanced prostate cancer |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 2.40 (95% CI: 1.49- 3.87) |
Effect on Pathways | Pathways Inlcude:-Hypoxia and p53 in the cardiovascular system Insulin-like growth factor (IGF) activity,regulation by insulin-like growth factor binding proteins (IGFBPs),TAp63 pathway,Delta Np63 pathway,Ghrelin-mediated regulation of food intake and energy homeostasis |
Experiment | Localised Vs Advanced Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | Meta analysis of 21 studies using, IGF1 and IGFBP3 as marker to predict advanced prostate cancer risk. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | NA |
Clinical | No |
Remarks | Metastudy |
Clinical Trial Number | NA |
Degree Of Validity | Metanalysis from 96 studies |
Technical Name | IGFBP3 |